Cognos Therapeutics
  • ABOUT
    • MISSION
    • BOARD of DIRECTORS
    • MANAGEMENT TEAM
    • IP MANAGEMENT
    • CLINICAL ADVISORY BOARD
    • REGULATORY AND COMPLIANCE
  • CLINICAL RELEVANCE
    • FOURTH MODALITY
  • PUBLICATIONS
  • NEWS
  • SHAREHOLDER PORTAL
    • SHAREHOLDER INFORMATION
  • CONTACT
Select Page
FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.

FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.

by cognosadminteam | Mar 28, 2015 | News

31 MAR, 2015 FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics’ Vision. Most medical treatments are designed for the “average patient” as a “one-size-fits-all approach”,...

Recent Posts

  • Cognos Therapeutics, Inc. To Be Publicly Listed On Nasdaq
  • Labroot’s Report Focuses on the Need To Develop Better Methods To Deliver Therapeutics to the Brain
  • Cognos Co-Founder and CIO Josh Shachar Discusses The Evolution of the Cognos Vision
  • Cognos Engages Maxim Group for Investment Banking and Financial Advisory Services
  • Cognos Announces Addition of New Clean Room To Expand Its Development Capabilites.

Recent Comments

    Archives

    • January 2023
    • January 2022
    • November 2021
    • October 2021
    • February 2019
    • January 2018
    • July 2017
    • September 2016
    • March 2015

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Cognos Therapeutics, Inc.

    10604 S La Cienega Blvd.
    Inglewood, CA 90304
    T: 310-641-2700
    E: info@cognosthx.com

    ADDITIONAL INFO

    Privacy Policy
    Terms of Use
    • Facebook
    • Twitter
    • Instagram
    • RSS

    Designed by Elegant Themes | Powered by WordPress